A prospective, multicenter, noncomparative, open label study to evaluate the safety, tolerability and efficacy of ertapenem sodium in the treatment of complicated urinary tract infections
Phase of Trial: Phase III
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Ertapenem (Primary)
- Indications Bacterial infections; Pyelonephritis; Urinary tract infections
- Focus Adverse reactions
- Sponsors Merck & Co
- 24 Mar 2009 Actual patient number (107) added as reported by ClinicalTrials.gov.
- 11 May 2007 New trial record.